A study finds that many patients with severe alopecia areata achieve meaningful hair regrowth after switching JAK inhibitors, ...

The MarketWatch News Department was not involved in the creation of this content. DOVER, Del., Nov. 6, 2025 /PRNewswire/ -- Eilean Therapeutics LLC, a biotechnology company developing next-generation ...

The Phase 1 study of PRT12396 is an open-label, multi-center, safety and efficacy study in patients with high-risk polycythemia vera (PV) and intermediate and high-risk myelofibrosis (MF). The primary ...

The MarketWatch News Department was not involved in the creation of this content. DOVER, Del., Dec. 17, 2025 /PRNewswire/ -- Eilean Therapeutics announced the advancement of ZE74-0282 into ...

Alopecia areata is a chronic autoimmune disorder causing non-scarring hair loss due to immune system attacks on hair follicles. Breakdown of immune privilege in hair follicles leads to infiltration by ...

Topical pumecitinib 3% gel shows strong efficacy and good tolerability in mild-to-moderate atopic dermatitis. Explore the ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. So, the first JAK inhibitor came to market ...

In certain patients, JAK inhibitor rescue medications seem to be more effective, researche ...

Editor's note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. First to, maybe step back and say, what is ...

A cohort study finds the risk for acne in patients on JAK inhibitors for atopic dermatitis was about 2.5 times greater than ...

Add Yahoo as a preferred source to see more of our stories on Google. Lynk Pharmaceuticals' next generation JAK inhibitor Lynk Pharmaceuticals has posted positive topline results from a Phase III ...